Rifaximin vs conventional oral therapy for hepatic encephalopathy: A meta-analysis

doi:10.3748/wjg.v18.i8.767

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 8

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7469)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

933

HTML

6091

Figures (1-4)

222

Tables (1-3)

223

Sum=7469

Feb 28, 2012 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (63)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Feb 28, 2012; 18(8): 767-777
Published online Feb 28, 2012. doi: 10.3748/wjg.v18.i8.767

Full Size Figure Download Figure

Figure 4 Serum ammonia levels at the end of the treatment protocols: rifaximin vs oral disaccharides, rifaximin vs other oral antibiotics and rifaximin vs control therapy which included the combination of oral disaccharides and other antibiotics. IV: Inverse variance.

Citation: Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs conventional oral therapy for hepatic encephalopathy: A meta-analysis. World J Gastroenterol 2012; 18(8): 767-777
URL: https://www.wjgnet.com/1007-9327/full/v18/i8/767.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i8.767